Pioneering Point-Of-Care Diagnostics
Nanopath was founded with the vision of commercializing a first-in-class technology platform to improve the health of women.
Cutting-Edge Pathogen Detection
Our platform harnesses the potential of an untapped biosensing modality to sensitively and specifically detect viral, bacterial, and fungal pathogens without the need for nucleic acid amplification, dramatically decreasing time-to-result.
Our platform also has the capability to simultaneously detect many targets using a single patient sample.
Interdisciplinary Science & Engineering
Our team is actively advancing the state-of-the-art in nanotechnology, biosensing, complex data analysis, optics, and molecular biology.
Nanopath’s breakthrough technology enables advanced laboratory-scale workflows to be implemented at the point-of-patient.
Our Product
Our cartridge and reader system brings comprehensive diagnostic testing directly to the doctor's office, fostering a proactive approach and enabling informed clinical decision-making.
Our product pipeline looks to improve women’s health by providing an integrated suite of assays to characterize pelvic and gynecologic infections.
Our initial focus is on infectious diseases that predominately affect women.
This technology has applications that extend well-beyond women's health.
Urinary Tract Infections
Human Papillomavirus
Vaginitis
Sexually Transmitted Infections
Award-Winning Innovation
Nanopath was awarded the 2022 Disruptive Technology Award by the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), the premier scientific body in laboratory medicine. This annual recognition is awarded for an “innovative testing solution that will transform patient care” and speaks to the groundbreaking nature of our approach.
